Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 26, 2026 09:00 ET | Source: Hemab Therapeutics, Inc.

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress

New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing;...
May 27, 2026 08:00 ET | Source: Hemab Therapeutics, Inc.

Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 27, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that reimagine the treatment...
May 21, 2026 07:00 ET | Source: Hemab Therapeutics, Inc.

Hemab Therapeutics Reports First Quarter 2026 Financial Results

Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq Granted Breakthrough Therapy Designation for sutacimig in Glanzmann thrombasthenia ...
May 04, 2026 16:01 ET | Source: Hemab Therapeutics, Inc.

Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, May 04, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that...
April 30, 2026 18:55 ET | Source: Hemab Therapeutics, Inc.

Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering

CAMBRIDGE, Mass. and COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Hemab Therapeutics Holdings, Inc. (Nasdaq: COAG), a clinical-stage biotechnology company developing therapies that...